S. Korea to approve Viagra generics

March 14, 2012

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

The Korea said generic products made by the three local firms have passed a "bioequivalence" test.

"The three firms are expected to get approval for production of Viagra generics probably this month or later," an official in charge of medicine tests told AFP on condition of anonymity.

"Our move has nothing to do with an ongoing patent row," he said, adding the watchdog is also expected to give the go ahead for more local firms.

Numerous domestic pharmaceutical firms have applied for approval to manufacture Viagra generics since it was introduced in in 1999.

US pharmaceutical giant Pfizer claims its patent, which involves using sildenafil, is valid until May 2014.

"Our patent covering the material is still valid," a Pfizer official in Seoul said, urging South Korean firms to recognise it.

Pfizer has yet to counter a lawsuit filed by CJ Cheiljedang, a domestic seeking to invalidate the patent.

"We plan to produce a generic Viagra regardless of the court's ruling, even if we have to compensate Pfizer in the future," an unnamed CJ Cheiljedang official told Yonhap news agency.

Explore further: Drug firm GSK fined $2.6 million for collusion

Related Stories

Drug firm GSK fined $2.6 million for collusion

October 24, 2011
South Korea's anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday.

US approves India's Ranbaxy to make generic Lipitor

December 1, 2011
Indian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.

India patent case threatens cheap drug supply: MSF

September 5, 2011
Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.